Apararenone clinical trials
Also written MT-3995.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses apararenone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses apararenone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)CompletedPhase 2Mitsubishi Tanabe Pharma CorporationNCT02923154Written as MT-3995How we know
- An Extended Treatment Study of MT-3995 in Patients With Diabetic NephropathyCompletedPhase 2Mitsubishi Tanabe Pharma CorporationNCT02676401Written as MT-3995 LowHow we know
- Efficacy and Safety of MT-3995 in Patients With Diabetic NephropathyCompletedPhase 2Mitsubishi Tanabe Pharma CorporationNCT02517320Written as MT-3995 LowHow we know
- Mass Balance Study of MT-3995CompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT02900235Written as MT-3995How we know
- Drug Interaction Study of Warfarin and MT-3995CompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT02531568Written as MT-3995How we know
- Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic NephropathyCompletedPhase 1/2Mitsubishi Tanabe Pharma CorporationNCT02205372Written as MT-3995How we know
- A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFRCompletedPhase 2Mitsubishi Tanabe Pharma CorporationNCT01756716Written as MT-3995 LowHow we know
- A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With AlbuminuriaCompletedPhase 2Mitsubishi Tanabe Pharma CorporationNCT01756703Written as MT-3995 LowHow we know
- Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic NephropathyCompletedPhase 1/2Mitsubishi Tanabe Pharma CorporationNCT01889277Written as MT-3995-LowHow we know
Codes
What other systems call apararenone · ClinicalTrials.gg INT001736
- MeSH (NLM) C000719999apararenoneOne source NLM
- UNII (FDA) 832663U2NBAPARARENONEConfirmed FDA, NLM, Wikidata
- Wikidata Q27269381apararenoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171675ApararenoneOne source FDA
- DrugBank DB15024One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719999 | apararenone | One source NLM |
| UNII (FDA) | 832663U2NB | APARARENONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27269381 | apararenone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171675 | Apararenone | One source FDA |
| DrugBank | DB15024 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.